Core Viewpoint - Hainan Huhuwawa Pharmaceutical Group Co., Ltd. faces significant internal control issues, leading to a negative audit opinion and a stock trading suspension, with a change in stock abbreviation to "ST Huhuwawa" starting April 30, 2025 [1][3][5] Financial Performance - For the fiscal year 2024, the company reported a revenue of 1.414 billion yuan, a year-on-year decrease of 21.26%, and a net profit attributable to shareholders of -274 million yuan, a staggering decline of 2629.23% [10] - In the first quarter of 2025, the company achieved a revenue of 337 million yuan, down 28.42% year-on-year, with a net profit of approximately 24.35 million yuan, a decrease of 11.23% [10] Internal Control Issues - The audit report from Lixin Certified Public Accountants highlighted three major areas of concern regarding internal controls, including the lack of complete financial data related to restated financial statements and issues with accounts receivable from key clients [3][5] - The company has been criticized for significant deficiencies in its internal control over financial reporting, resulting in a negative opinion from the auditors [5] Management Changes - The company's general manager, Zhang Mingrui, resigned for personal reasons less than two months after taking office, marking a period of instability in leadership [2][6] - This resignation follows the earlier departure of Liu Jingping from the general manager position, who remains as chairman and has been a key figure in the company since its inception [7][8] Related Transactions - In 2024, the company purchased eight R&D projects from Hainan Zhongwang Medical Technology Development Co., Ltd. for 42.0537 million yuan, raising concerns due to familial ties between the company's actual controller and the legal representative of the vendor [4]

Core Viewpoint - ST Lingda's 2024 annual report has raised significant concerns among board members and management regarding its authenticity and internal controls [1][2]. Financial Performance - ST Lingda reported an operating income of 0.61 million, a year-on-year decrease of 92.71% - The net profit attributable to shareholders was -9.50 billion, a year-on-year decrease of 262.42% [2]. Internal Control Issues - The internal control audit report for 2024 received a negative opinion, indicating major deficiencies in internal controls related to external guarantees and subsidiary management [2]. - The company has faced continuous failures in internal control reports for two consecutive years, limiting the ability of management to express opinions [1][2]. Management and Board Concerns - Board member Bai Jianghong expressed doubts about the authenticity of the report and stated he could not provide an opinion due to lack of involvement in actual operations [2]. - Bai Jianghong and another board member, Huang Jianchuan, abstained from voting on the annual report and other related proposals, citing concerns over internal controls and financial expertise [2][4]. Business Operations - The main business of ST Lingda is related to the photovoltaic industry, with a significant portion of revenue historically coming from its subsidiary, Jiazhi Jiayue New Energy Technology Co., Ltd. [3]. - Jiazhi Jiayue's first-phase battery project has been suspended since March 14, 2024, due to declining prices in the photovoltaic supply chain, with no immediate plans for resumption [3]. Previous Board Actions - Bai Jianghong has a history of opposing or abstaining from votes on various reports, including the 2024 semi-annual and third-quarter reports, citing concerns over financial data accuracy and potential management misconduct [4][5].